1. MS Highlights From the 2017 Annual Neurology Meeting

2. Introduction

3. JCV-Positive Patients: Switching From Natalizumab

4. IFNβ-1a tiw Reduces Disease Activity

5. Ocrelizumab Phase 2 Trial

6. Ocrelizumab Phase 2 Trial: MRI Results

7. Conclusions

8. MS Highlights From the 2017 Annual Neurology Meeting

9. Spinal Cord Gray Matter Atrophy

10. Spinal Cord Gray Matter Atrophy (cont)

11. Vitamin D Polymorphisms and Risk of MS

12. Vitamin D Polymorphisms and Risk of MS (cont)

13. Microbiome in Relapsing MS

14. Reserve in MS

15. Reserve in MS: Results

16. Conclusions

17. MS Highlights From the 2017 Annual Neurology Meeting

18. Introduction

19. Defining NEPAD

20. ORATORIO: Ocrelizumab Reduces Disease Activity

21. Siponimod Safety

22. ASCEND: Improvement in Disability?

23. Conclusions

24. MS Highlights From the 2017 Annual Neurology Meeting

25. Opicinumab: SYNERGY Efficacy

26. Opicinumab: SYNERGY Efficacy (cont)

27. MIS416 in SPMS

28. Cladribine: ORACLE-MS Open-Label Maintenance Period

29. Cladribine Efficacy in High Disease Activity

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)

33. Abbreviations (cont)